Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer

Journal of Clinical Pharmacology

Volumn 52, Issue 5, 2012, Pages 691-703

  Gupta, Manish ^a   Lorusso, Patricia M ^b   Wang, Bei ^a   Yi, Joo Hee ^a   Burris, Howard A ^c   Beeram, Muralidhar ^d   Modi, Shanu ^e   Chu, Yu Waye ^a   Agresta, Samuel ^a   Klencke, Barbara ^a   Joshi, Amita ^a   Girish, Sandhya ^a  

^a GENENTECH INC   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d CTRC Institute for Drug Development   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

antibody drug conjugate; population pharmacokinetics; T DM1; trastuzumab; trastuzumab emtansine

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB EMTANSINE;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; BREAST CANCER; COMPARTMENT MODEL; DEMOGRAPHY; DRUG CLEARANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATHOPHYSIOLOGY; TUMOR VOLUME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ASPARTATE AMINOTRANSFERASES; BODY WEIGHT; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; IMMUNOTOXINS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MAXIMUM TOLERATED DOSE; MAYTANSINE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN BINDING; RECEPTOR, ERBB-2; SERUM ALBUMIN; TREATMENT OUTCOME; TUBULIN MODULATORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84860307997     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011403742     Document Type: Article

References (27)

1. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010 ; 28: 92-98
2. Lewis-Phillips GD, Li G, Dugger DL. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008 ; 6: 9280-9290
3. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010 ; 28: 2698-2704
4. BurrisHRugoHVukelkaS. Phase II study of the antibody drug conjugate trastuzumab-DM1 (T-DM1) for the treatment of HER2-positive breast cancer following prior HER2-directed therapy. J Clin Oncol. 2011;29:398-405.
5. Krop IE, LoRusso PM, Miller KD, et al. A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy. Presented at: European Society for Medical Oncology Annual Symposium ; Milan, Italy ;..
6. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992 ; 52: 127-131
7. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005 ; 5: 543-549 (Pubitemid 41258574)
8. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005 ; 23: 1137-1146 (Pubitemid 41486395)
9. Remillard S, Rebhun LI, Howie GS, et al. Antimitotic activity of the potent tumor inhibitor maytansine. Science. 1975 ; 189: 1002-1005
10. Cassady JM, Chan KK, Floss HG, et al. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo). 2004 ; 52 (1). 1-26 (Pubitemid 41685545)
11. South San Francisco: Genentech, Inc ; 2007:
12. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 ; 344: 783-792 (Pubitemid 32222155)
13. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007 ; 357: 39-51 (Pubitemid 47026733)
14. Dieras V, Harbeck N, Albain K, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Presented at: San Antonio Breast Cancer Symposium ; San Antonio, TX ;..
15. Krop IE, Modi S, Elias A, et al. A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel, and pertuzumab in patients with HER2-positive, locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. Presented at: San Antonio Breast Cancer Symposium ; San Antonio, TX ;..
16. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron. 1992 ; 62: 249-256
17. NONMEM User's Guide, Parts I-V. Beal SL Boeckman AJ Sheiner LB, ed. San Francisco: University of California at San Francisco ; 1988-1992.
18. Lindbom L, Pihlgren P, Jonsson EN, et al. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005 ; 79: 241-257 (Pubitemid 41196689)
19. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. Am Assoc Pharm Sci J. 2009 ; 11: 558-569
20. Bruno R, Washington CB, Lu J-F, et al. Population pharmacokinetics of trastuzumab in patients with HER2 metastatic breast cancer. Cancer Chemo Pharm. 2006 ; 56: 361-369
21. Ng CM, Lum BL, Gimenez C, et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006 ; 23: 1275-1284 (Pubitemid 43946149)
22. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008 ; 62: 779-786
23. Food and Drug Administration. Guidance on Pharmacokinetics in Patients With Impaired Renal Function. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM072127.pdf
24. Jumbe NL, Xin Y, Leipold DD, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn. 2010 ; 37: 221-242
25. Parsons K, Crocker L, Leipold D, et al. Trastuzumab directed cytotoxic therapy: efficacy against HER2-positive trastuzumab-insensitive breast cancer models and enhanced response to trastuzumab-sensitive models. Presented at: American Association for Cancer Research (AACR) Annual Meeting ; Los Angeles, CA ;..
26. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol. 2007 ; 179: 4580-4588
27. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010 ; 49: 633-659